<DOC>
	<DOCNO>NCT00017641</DOCNO>
	<brief_summary>OBJECTIVES : I . Determine safety immune ablation high-dose cyclophosphamide anti-thymocyte globulin follow peripheral blood stem cell support patient systemic lupus erythematosus .</brief_summary>
	<brief_title>Phase I Study Immune Ablation CD34+ Peripheral Blood Stem Cell Support Patients With Systemic Lupus Erythematosus</brief_title>
	<detailed_description>PROTOCOL OUTLINE : Patients receive cyclophosphamide IV 1 hour 2 dos . Patients receive filgrastim ( G-CSF ) subcutaneously ( SC ) begin 24 hour completion cyclophosphamide continue leukapheresis complete . Leukapheresis continue daily target number cell harvest . CD 34+ cell isolated peripheral blood stem cell ( PBSC ) vitro . Patients receive cyclophosphamide IV 1 hour day -5 -2 , anti-thymocyte globulin IV 10 hour day -4 -2 , G-CSF SC begin day 0 continue blood count recover . Patients undergo reinfusion CD34+ PBSC day 0 . Patients follow weekly 90 day , monthly 1 year , 2 year .</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Diagnosis systemic lupus erythematosus 1 follow malignant feature : Nephritis ( WHO class III IV ) Failed NIH shortcourse cyclophosphamide therapy Vasculitis/immune complex deposition cause end organ sign symptom ( e.g. , cerebritis , transverse myelitis , pulmonary hemorrhage , cardiac failure , renal failure ) Hematologic cytopenia immune mediate uncontrolled conservative measure follow : Transfusiondependent anemia untransfused hemoglobin le 8 g/dL Platelet count le 40,000/mm3 ( without transfusion ) Granulocyte count le 1,000/mm3 Catastrophic antiphospholipid syndrome Patient Characteristics Cardiovascular : LVEF least 35 % No lupusinduced myocarditis No history unstable angina Pulmonary : FEV1/FVC least 50 % predict DLCO least 50 % predict Other : HIV negative No prior concurrent malignancy except localize basal cell squamous cell skin cancer No uncontrolled diabetes mellitus No medical illness would preclude study No psychiatric illness mental deficiency would preclude study No known hypersensitivity E. coliderived protein Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>November 2003</verification_date>
	<keyword>arthritis &amp; connective tissue disease</keyword>
	<keyword>immunologic disorder infectious disorder</keyword>
	<keyword>rare disease</keyword>
	<keyword>systemic lupus erythematosus</keyword>
</DOC>